曲妥珠单抗联合阿帕替尼对胃癌患者血清肿瘤标志物水平及生命质量的影响

Effect of trastuzumab combined with apatinib on serum tumor markers and quality of life in patients with gastric cancer

目的探讨曲妥珠单抗联合阿帕替尼对胃癌患者血清肿瘤标志物水平及生命质量的影响。方法选取2018年6月至2020年6月本院收治的84例胃癌患者作为研究对象,采用随机数字表法分为两组,各42例。对照组予以曲妥珠单抗治疗,观察组在对照组基础上联合阿帕替尼治疗。比较两组血清肿瘤标志物水平[糖类抗原19-9(CA19-9)、糖类抗原125(CA125)、癌胚抗原(CEA)]、生命质量评分及不良反应发生情况。结果治疗后,两组CA19-9、CEA、CA125水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组生命质量评分均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为4.76%,低于对照组的21.43%,差异有统计学意义(P<0.05)。结论曲妥珠单抗联合阿帕替尼治疗胃癌疗效显著,可降低肿瘤标志物水平,提高患者生命质量,且不良反应较少。

Objective To investigate the effects of trastuzumab combined with apatinib on serum tumor markers and quality of life in patients with gastric cancer.Methods 84 patients with gastric cancer who were admitted to our hospital from June 2018 to June 2020 were selected as the research subjects,and they were divided into two groups according random number table method,with 42 cases in each group.The control group was treated with trastuzumab,and the observation group was treated with apatinib on the basis of the control group.The levels of serum tumor markers(carbohydrate antigen 19-9[CA19-9],carbohydrate antigen 125[CA125],carcinoembryonic antigen[CEA]),quality of life and the occurrence of adverse reactions were compared between the two groups.Results After treatment,the levels of CA19-9,CEA and CA125 in the two groups were lower than those before treatment,and the observation group was lower than the control group,the difference was statistically significant(P<0.05).After treatment,the quality of life scores of the two groups were higher than those before treatment,and the observation group was higher than the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 4.76%,which was lower than 21.43%in the control group,and the difference was statistically significant(P<0.05).Conclusion Trastuzumab combined with apatinib in the treatment of gastric cancer can enhance the efficacy,reduce the level of tumor markers,improve the quality of life of patients,and less toxic adverse reactions.